On Apr. 22, 2021, RELIEF THERAPEUTICS and AdVita Lifescience announced that the first patient was expected to be enrolled in a phase 2 trial evaluating the inhaled formulation of RLF-100 for the prevention of COVID-19-related acute respiratory distress syndrome (ARDS).

The study, ﾓInhaled Aviptadil for the Prevention of COVID-19 Related ARDSﾔ (NCT 04536350), was a randomized, double-blind, placebo-controlled phase 2 trial being conducted at several clinical sites in Switzerland. The trial was expected to enroll 80 patients, who received either RLF-100 together with standard of care or placebo plus standard of care.